Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)

Trial Profile

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke
  • Focus Adverse reactions
  • Acronyms XARENAL
  • Sponsors Bayer
  • Most Recent Events

    • 18 Jan 2019 Planned primary completion date changed from 2 Dec 2019 to 1 Dec 2020.
    • 20 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 26 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top